公司資料
Kiniksa 股價、新聞與催化劑
- 股票代碼:
- KNSA
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
79.18 USD (+3.17%)
收盤價
最後更新: 2026年8月17日
3.61B USD
市值
股價為何變動
As of Aug 17, 2026, KNSA closed up 3.17% at $79.18. No new same-company headline was identified in the current news window.
公司概覽
IL-1 Cardiovascular Franchise
Kiniksa Pharmaceuticals develops and commercializes therapies for diseases with strong biological rationale, with an emphasis on cardiovascular inflammation. Its portfolio is centered on blocking interleukin-1 alpha and beta signaling.
ARCALYST
ARCALYST, or rilonacept, is a weekly subcutaneous IL-1 cytokine trap approved for recurrent pericarditis and selected autoinflammatory disorders. It provides Kiniksa’s commercial foundation in pericarditis.
KPL-387
KPL-387 is an IL-1 receptor 1 monoclonal antibody being developed for recurrent pericarditis. Its target profile is a monthly self-administered injection, and a Phase 2/3 program is assessing dose selection and transition from standard therapy.
KPL-1161
KPL-1161 is an Fc-modified IL-1 receptor antibody in preclinical development. The molecule is designed for quarterly subcutaneous dosing and could extend the franchise toward substantially less frequent administration.
未來催化劑
- Phase 2 dose-focusing data for KPL-387 expected in the second half of 2026.
- Initiation of the Phase 3 pivotal KPL-387 trial expected by year-end 2026.
- Initiation of a Phase 1 trial of KPL-1161 expected by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。